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Background: A strong relationship between insomnia and painful disorders has been found, but it is still unclear
whether chronic pain leads to insomnia. There is a need of large-scale prospective studies to evaluate if there is a
causal relationship between painful disorders and insomnia.
Methods: All inhabitants aged ≥ 20 years in Nord-Trøndelag County of Norway were invited to participate in two
surveys (n = 92,566 and 93,860, respectively). 27,185 subjects participated in both surveys, and 19,271 of these were
insomnia-free at baseline (population at risk). Using logistic regression, we evaluated the influence of headache,
CMSCs and coexisting headache and CMSCs on the subsequent risk of insomnia.
Results: Compared to subjects without headache and CMSCs, there was an increased risk of insomnia among
those with headache, most pronounced among those with headache ≥ 7 days / month (OR = 2.2, 95% CI = 1.9 – 2.6).
Similarly, an increased risk among those with CMSCs was found, most evident for those with widespread CMSCs
(OR = 2.0, 95% CI = 1.8 – 2.2). Having coexistent CMSCs and headache (OR = 2.0, 95% CI = 1.8 – 2.2) predisposed
more strongly to insomnia than having headache (OR = 1.5, 95% CI = 1.3 – 1.6) and CMSCs
(OR = 1.6, 95% CI = 1.4 – 1.7) alone.
Conclusion: In this prospective study headache and CMSCs were risk factors for insomnia 11 years later.
Keywords: Prospective, Headache, Chronic musculoskeletal complaints, Risk factor, InsomniaBackground
Insomnia is associated with considerable suffering for
the affected individual [1] with additional impact on the
society at large [2]. A strong relationship between in-
somnia and painful disorders have been reported [3],
and studies indicate that pain not only might be a risk
factor for insomnia but that the two disorders reciprocal
influence and exacerbate each other [3]. It is also likely
that when insomnia and chronic pain occur together
their consequences are even more devastating [4]. In
clinical studies acute painful stimuli applied to healthy
subjects during sleep resulted in transient arousals [5],* Correspondence: sivstein@stud.ntnu.no
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in any medium, provided the original work is pwhile chronic pain patients had poorer sleep than con-
trols in terms of sleep latency, sleep efficiency and awak-
enings after sleep onset [6].
Although there is a well known association between
insomnia and painful disorders it is still unclear whether
chronic pain leads to insomnia [3]. The few longitudinal
studies that do exist on this topic [7-10] include rela-
tively few participants or lack validated diagnostic cri-
teria of insomnia. The only study that included subjects
free of sleep disturbance (n = 437) at baseline, reported
that unspecified bodily pain was a risk factor for new-
onset insomnia at follow-up one year later [8]. However,
to the best of our knowledge, no large follow-up study
has evaluated the influence of primary headaches and
chronic musculoskeletal complaints (CMSCs) on the risk
of insomnia.s an Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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prospective cohort study, using data from two large-
scale health surveys carried out in Nord-Trøndelag
county of Norway in 1995–1997 and 2006–2008. The
main objective was to evaluate the association between
primary headaches, CMSCs and coexisting headache and
CMSCs at baseline and the subsequent risk of insomnia
among men and women at follow-up 11 years later.Methods
The population
Nord-Trøndelag is one of 19 counties in Norway, and its
geography and demography is fairly representative for
the country [11]. The Nord-Trøndelag Health Survey
(“Helseundersøkelsen i Nord-Trøndelag”: HUNT) is a
longitudinal cohort study in which all inhabitants ≥20
years old of Nord-Trøndelag have been invited to
participate.The HUNT 2 study
In HUNT 2 (performed between August 1995 and June
1997) each person completed extensive questionnaires
eliciting information on health problems. Among a wide
range of topics in the first questionnaire (Q1) were edu-
cation, physical activity, smoking, alcohol, and anxiety
and depression (measured by the Hospital Anxiety and
Depression Scale (HADS)) [12]. Details of the phrasing
of these questions have been described previously
[13-17]. In the present paper, educational level was cate-
gorized according to duration (< 13 years vs. ≥ 13 years),
work-status as paid work (yes vs. no), and sick leave dur-
ation the last 12 months, categorized as 0 weeks, < 2
weeks or ≥ 2 weeks. Cigarette smoking was categorized
as current daily smoking (yes vs. no). Reponses to ques-
tions on physical activity were categorized according to
duration and intensity of exercise per week with the ex-
tremes ≥ 3 hours hard physical activity and physical in-
activity. Caffeine consumption was subdivided into two
groups (highest quartile vs. other quartiles). Alcohol
consumption was measured by the CAGE questionnaire
[18], using a cutoff ≥ 1 to indicate possible alcohol
abuse. Subjects suffering from gastrointestinal (GI) com-
plaints (yes vs. no) were defined as subjects with some
or much reflux symptoms and/ or diarrhea and /or con-
stipation and / or nausea. In Q2 participants were asked
if they had used medication (for any condition of any
type) daily or almost daily during the last 12 months. In
the following question they were asked for how many
months they had taken specified drugs, including antide-
pressants, sedatives and hypnotics. We categorized the
use of drugs as 0 months vs. ≥ 1 months. They were spe-
cifically asked how often, during the last month, they
had used sedatives or hypnotics. This question wasamong those used to define the insomnia-free popula-
tion in HUNT 2.Headache diagnoses
Q2 included 13 questions about headache. All partici-
pants were asked the screening question “Have you suf-
fered from headache during the last year?” Subjects
answering “yes” were then asked to respond to the other
headache-related questions, mainly designed to deter-
mine whether subjects met the migraine criteria of the
International Headache Society (IHS) [19]. HUNT 2 did
not include any question about pain intensity, and criter-
ion C of the migraine diagnosis had to be modified ac-
cordingly [11]. Headache not fulfilling the migraine
criteria were classified as non-migraineous headache.
Headache was defined as frequent if it occurred > 7 days
/ month. The validity of the questionnaire based head-
ache diagnoses in HUNT 2 has been evaluated previ-
ously [11]: For migraine, the sensitivity was 69% and
specificity 89% (kappa value 0.59, 95% CI =0.47-0.71);
for non-migraineous headache, the sensitivity was 61%,
specificity 81% (kappa 0.43, 95% CI=0.29-0.57), and for
headache > 7 days/month the sensitivity was 56% and
specificity was 91% (kappa 0.50, 95% CI 0.34-0.66).Chronic musculoskeletal complaints (CMSCs)
In Q1, subjects were asked the screening question:
“Have you during the last year continuously for at least 3
months had pain and/or stiffness in muscles and joints?”
The reliability of this question has been reported previ-
ously [20] and the chance-adjusted agreement (kappa
value) was 0.63 (95% CI = 0.53-0.73).
Subjects who answered “yes” were also asked to mark
the localization of this pain (neck, shoulders, elbows,
wrist/hands, upper back, lower back, hips, knees, and/or
ankles/feet). The nine anatomical regions were derived
from the Nordic Questionnaire [21] evaluated previously
and found to give reliable information for low back,
upper limb and neck on the presence of symptoms dur-
ing the past year [22].
Subjects who answered “yes” to the screening question
were considered to have CMSCs. Widespread CMSCs
were defined according to the 1990 American College of
Rheumatology (ARC) as CMSCs from all of the follow-
ing three regions: axial skeleton (neck, upper back, or
lower back), above the waist (neck, shoulders, elbows,
wrist/hands, or upper back) and below the waist (lower
back, hips, knees, or ankles/feet) [23]. In HUNT 2 par-
ticipants were not asked to distinguish between pain in
the left and right side of the body. The change-adjusted
agreement (kappa value) for widespread CMSCs has re-
cently been estimated to 0.48 (95% CI = 0.38-0.64) [20].
Subjects with CMSCs who did not meet the criteria for
Ødegård et al. The Journal of Headache and Pain 2013, 14:24 Page 3 of 10
http://www.thejournalofheadacheandpain.com/content/14/1/24widespread CMSCs were defined as non-widespread
CMSCs.
The definition of insomnia-free in HUNT 2
In Q2, subjects were asked two questions about the fre-
quency of sleep onset insomnia (“Have you had prob-
lems falling to sleep in the last month?”) and sleep
maintenance problems (“During the last month, did you
ever wake up too early, not being able to fall asleep
again?”). There were four possible responses: 0 = never,
1 = occasionally, 2 = often, or 3 = almost every night.
These two insomnia symptoms were dichotomized into:
0 = “no” (never / occasionally) or 1 = “yes” (often / al-
most every night). These two answer scores were added,
and subjects with a sum score of 0 were considered un-
likely to have insomnia [24-26]. In the present study
insomnia-free was defined as those who had a sum score
of 0 on the two insomnia questions and had never used
hypnotics or sedatives the last month.
The HUNT 3 study
HUNT 3 (performed between October 2006 and June
2008) was to a large extent a replication of HUNT 2.
Insomnia diagnosis
HUNT 3 included three insomnia questions in Q2:
“How often during the last three months have you expe-
rienced: 1) difficulty falling asleep at night, 2) several
awakenings during the night and 3) wake up to early
and were not able to fall asleep again. The response al-
ternatives were: 0 = never or seldom, 1 = sometimes, 2 =
several times a week. The reliability of these three in-
somnia questions in HUNT 3 has been assessed previ-
ously, and found to be moderate with kappa-values of
0.44 (95% CI = 0.35 – 0.52) and 0.38 (95% CI = 0.31 –
0.46) and 0.35 (95% CI = 0.26 – 0.46) respectively [27].
To create a DSM-IV based proxy insomnia [24] diagno-
sis the three questions were first dichotomized into two
possible responses: 0 = “no” (never, seldom or some-
times) and 1 = “yes” (several times a week). The insom-
nia questions were then added, and subjects with a score
≥ 1 were considered likely to have insomnia.
Headache
The Q2 also included the same headache-screening
question that was used in HUNT 2. For the
questionnaire-based status as a headache sufferer, a sen-
sitivity of 88%, a specificity of 86%, and a kappa value of
0.70 have been found [28].
Study population
In HUNT 2, 65, 237 (69.5%) of 92,566 invited individuals
answered Q1, and 50,738 (54.8%) answered the insomnia
questions in Q2 and were classifiable according to painstatus. Details of non-responders have been described
previously [29]. In HUNT 3, 50,807 (54.1%) of the
93,860 invited adults answered Q1, and 40,534 (43.2%)
completed the insomnia questions in Q2.
Among the 65,237 participants in HUNT 2, 10,507
had died, 240 had emigrated and 1 had disappeared by
the time of HUNT 3. Out of all the 54,789 eligible
HUNT 2 participants, 69% of men and 72% of women
also participated in HUNT 3. The mean time of follow-
up between HUNT 2 and HUNT 3 was 11 (range 9–13)
years. Among the 50,738 who answered the insomnia in
HUNT 2, 26,151 answered the insomnia related ques-
tions in both surveys. Of these 19,271 (74%) were con-
sidered free of insomnia in HUNT 2 (sum score of 0 on
the proxy insomnia diagnosis and did not report any use
of sleep medication or sedatives) and were defined as
the population at risk. The remaining 6,880 had
insomnia-symptoms at baseline in HUNT 2. The flow
chart of participants in HUNT 2 and HUNT 3 is shown
in Figure 1.
Ethics
The study was approved by the Regional Committee for
Ethics in Medical Research.
Statistics
In the population at risk, we used multivariate logistic
regression (with 95% confidence intervals [CI]) to evalu-
ate the relative influence of headache, CMSCs (alone or
in combination with each other) in HUNT 2 on the risk
of insomnia at follow-up. Comparisons were done be-
tween men and women to detect possible gender differ-
ences. To evaluate the probability of a linear relationship
between headache frequency at baseline and insomnia at
follow up, we performed trend analyses by treating fre-
quency of headache (three categories) as a single ordinal
variable. The trend test was considered statistically sig-
nificant at p < 0.05.
In the multivariate analyses we initially adjusted for
age and gender. In a second set of analyses additional
adjustments were done for previously identified potential
confounding factors [2,10,13-16,29], in particular educa-
tion level, work-status, sick leave, level of physical activ-
ity, daily use of tobacco, alcohol overuse, high coffee-
consumption, anxiety and depression, antidepressants,
GI-complaints, body mass index (BMI) and systolic
blood pressure (BP). The variables were categorized as
described in the method section (age, BMI and systolic
BP as continuous variables), and included in the statis-
tical model one at a time. Potential confounders were
excluded in the final analyses if the OR changed less
than 0.1 in analyses regarding headache and CMSCs re-
spectively. Subjects with incomplete data regarding one
or several variables were included in the analysis (as a
93,860
Invited age > 20 years 
40,534  (43%)
Answered insomnia 
questions in HUNT 3
65,237 (70%)
Answered Q1 HUNT 2
26,151
Answered insomnia section in 
HUNT 2 and HUNT 3 and 
classified according to pain 
status in HUNT 2 
50,738 (55%)
Answered insomnia items in 
Q2 and pain questions 
19,271
Insomnia-free in HUNT 2 
(population at risk)
92,566
Invited age > 20 years 
10,738              
Deceased or moved 
before HUNT 3
40,255
Participated in both 
HUNT 2 and HUNT 3
HUNT 2 1995-1997 HUNT 3 2006-2008 
6880
With insomnia in HUNT 2
50,807 (54%)
Answered Q1 HUNT 3
Figure 1 The flow of participants in HUNT 2 and HUNT 3.
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bias.
In supplementary adjusted analyses, we evaluated the
influence of headache status in HUNT 2 and HUNT 3
on the odds of having insomnia in HUNT 3.
The statistical analyses were performed with the Pre-
dictive Analytics Software (PASW), Statistics version
17.0 by Inc., an IBM Company (Chicago, IL, USA).
Results
Demographic and clinical characteristics of the popula-
tion at risk (n=19,271) are given in Table 1.
Headache
In the multivariate analysis, adjusting for age and sex,
GI-complaints and total HADS score, headache at base-
line was associated with a 2-fold risk of insomnia (OR =
1.7, 95% CI = 1.6 – 1.9) compared to subjects withoutheadache and CMSCs. Compared to subjects without
headache and CMSCs those with headache < 7 days /
month had a 70% increased risk, while those with head-
ache ≥ 7 days had a 120% increased for insomnia
(Table 2). There was a significant relationship (p trend
<0.001) between the headache frequency at baseline and
the risk of insomnia 11 years later (Table 2). There were
no significant differences between headache types or
gender (Table 2).
Chronic musculoskeletal complaints
In age-, sex-, GI-complaints and total HADS score ad-
justed analyses, CMSCs at baseline was associated with a
2-fold risk of insomnia at follow-up (OR = 1.8; 95% CI =
1.6 – 1.9) compared to subjects without headache and
CMSCs. Compared to subjects without headache and
CMSCs non-widespread CMSCs gave a 60% increased
risk of insomnia, while a 100% increased risk was observed
Table 1 Baseline characteristics of the population at risk1
in HUNT-2
Variables
Number of participants 19,271
Age (mean [SD], missing = 0) 45.8 [12.7]
Gender (% women, missing = 0) 54.7
Married (%, missing = 12) 69.4
Education ≥ 13 years (%, missing = 275) 35.6
Paid work (%, missing = 167) 73.6
High level of physical activity2 (%, missing = 4150) 9.7
BMI (mean [SD], missing = 35) 26.0 [3.8]
Systolic BP (mean [SD], missing = 46) 133.3 [18.4]
Daily use of tobacco (%, missing = 1857) 27.2
Alcohol overuse (cage score ≥ 1) (%, missing = 2287) 16.2
Total HADS-score (mean [SD], missing = 1978) 6.6 [4.7]
GI-complaints3 (%, missing 517) 48.5
1: Population at risk = Insomnia-free subjects (defined as subjects who have
never or occasionally had sleep onset or terminal insomnia during the last
month, and do not use sleep medication) in HUNT-2 who answered the
questions about headache and musculoskeletal complaints.
2: High level of physical activity = Strenuous physical activity ≥ 3 hours / week.
3: GI-complaints: Some or much reflux symptoms and/ or diarrhea and /or
constipation and / or nausea.
Table 2 Influence of headache (related to type and frequency
population at risk (n = 19,271)
Both g
Insomn
n, total = 14,639 n = 3069 OR (95%
No headache or CMSCs 7263 1080 1.0 (ref
Headache4 7376 1989 1.7 (1.6
< 7 days / month 6202 1589 1.7 (1.5
≥ 7 days / month 1174 400 2.2 (1.9
p-trend <0.001
Non migraineous headache 4963 1278 1.7 (1.5
< 7 days / month 4279 1049 1.6 (1.4
≥ 7 days / month 684 229 2.2 (1.8
p-trend <0.001
Migraine 2413 711 1.9 (1.7
< 7 days / month 1923 540 1.8 (1.6
≥ 7 days / month 490 171 2.2 (1.7
p –trend <0.001
1Data is adjusted for age, gender, anxiety, depression (total HADS-score) and GI-com
2Data is adjusted for age, anxiety, depression (total HADS-score) and GI-complaints.
3: Insomnia = During the last three months difficulty falling asleep at night and / or
able to fall asleep again several days a week.
4: Headache = Subjects with headache only or headache and CMSCs combined.
Missing data: 155 subjects with pure headache (= 4.2%) and 182 subjects with coex
headache frequency.
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were no significant gender differences (Table 3).
Combined headache and chronic musculoskeletal
complaints
Compared to subjects without headache and CMSCs,
pure headache < 7 days / month at baseline gave a 40%
increased risk of insomnia, while pure headache ≥ 7 days
/ month gave a 110% increased risk (Table 4). The com-
bination of headache and CMSCs predisposed more
strongly to insomnia than headache alone (Table 4). This
effect was most prominent and significant (non-overlap-
ping CIs) for headache <7 days / month with a 90%
increased risk of insomnia compared to subjects free of
headache and CMSCs at baseline (Table 4). Regarding
subjects with headache ≥ 7 days / month having CMSCs
did not have any strong influence the risk for insomnia
(OR = 2.2, 95% CI = 1.9 – 2.7), compared to headache
alone (overlapping CIs in Table 4).
As shown in Table 5, compared to subjects without
headache and CMSCs, the coexistence of headache ≥ 7
days / month and CMSCs had a stronger (significant)
influence on the risk of insomnia (overall OR = 2.2, 95%
CI = 1.9 – 2.6), than pure CMSCs (overall OR = 1.6,
95% CI = 1.4 – 1.7). This effect was evident for both
non-widespread CMSCs and widespread CMSCs, but
only significant for the former (Table 5).) on the risk of insomnia in HUNT-3 among the
ender1 Women2 Men2
ia3 Insomnia3 Insomnia3
CI) n = 2020 OR (95% CI) n = 1049 OR (95% CI)
) 581 1.0 (ref) 499 1.0 (ref)
– 1.9) 1439 1.8 (1.6 – 2.0) 550 1.7 (1.4 – 1.9)
– 1.8) 1142 1.7 (1.5 – 1.9) 447 1.6 (1.4 – 1.8)
– 2.6) 297 2.2 (1.8 – 2.7) 103 2.2 (1.7 – 2.8)
<0.001 <0.001
– 1.8) 884 1.7 (1.5 – 1.9) 394 1.6 (1.4 – 1.9)
– 1.8) 726 1.6 (1.4 – 1.8) 323 1.6 (1.3 – 1.8)
– 2.7) 158 2.2 (1.7 – 2.8) 71 2.3 (1.6 – 3.1)
<0.001 <0.001
– 2.1) 555 2.0 (1.7 – 2.3) 156 1.7 (1.4 – 2.1)
– 2.1) 416 1.9 (1.6 – 2.2) 124 1.6 (1.3 – 2.1)
– 2.7) 139 2.2 (1.7 – 2.9) 32 2.0 (1.3 – 3.1)
<0.001 <0.001
plaints.
several awakenings during the night and / or wake up to early and were not
isting headache and CMSCs (= 4.5%) did not answer the question on
Table 3 Influence of CMSC on the risk of insomnia in HUNT-3 among the population at risk (n = 19,271)
Both gender1 Women2 Men2
Insomnia3 Insomnia3 Insomnia3
n, total = 15,604 n = 3372 OR (95% CI) n = 2025 OR (95% CI) n = 1347
No headache or CMSCs 7263 1080 1.0 (ref) 581 1.0 (ref) 499 1.0 (ref)
CMSCs4 8341 2292 1.8 (1.6 – 1.9) 1444 1.9 (1.6 – 2.1) 848 1.7 (1.5 – 1.9)
Non widespread CMSC 4219 992 1.6 (1.4 – 1.7) 584 1.6 (1.4 – 1.9) 408 1.5 (1.3 – 1.8)
Widespread5 CMSC 4122 1300 2.0 (1.8 – 2.2) 860 2.1 (1.8 – 2.4) 440 1.9 (1.6 – 2.2)
1Data is adjusted for age, gender, anxiety, depression (total HADS-score) and GI-complaints.
2Data is adjusted for age, anxiety, depression (total HADS-score) and GI-complaints.
3: Insomnia = During the last three months difficulty falling asleep at night and / or several awakenings during the night and / or wake up to early and were not
able to fall asleep again several days a week.
4,1: CMSCs is defined as the subjects who answered “yes” to the screening question: “Have you during the last year continuously for at least 3 months had pain
and / or stiffness in muscles and joints?”
4,2: CMSCs = Subjects with CMSCs only or headache and CMSCs combined.
5: Widespread CMSCs = CMSCs from all of the following three regions: axial skeleton (neck, upper back, or lower back), above the waist (neck, shoulders, elbows,
wrist/hands, or upper back) and below the waist (lower back, hips, knees, or ankles/feet).
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Individuals with headache in both surveys were more
strongly associated to insomnia in HUNT 3 (OR=2.0;
95% CI 1.8-2.2) than those with headache in HUNT 3
only (OR=1.7, 95% CI 1.5-1.9) and those with headache
in HUNT 2 only (OR=1.3, 95% CI 1.1-1.4), using
headache-free subjects in both surveys as a reference
group.Table 4 Risk of insomnia1 at 11-year follow-up according to t
frequency) and CMSCs2 (yes/no)
Pure headache (no CM
Insomnia1
total, n = 10,775 n = 1896 OR (9
No headache or CMSCs 7263 1080 1.0 (r
Headache 3512 786 1.5 (1
< 7 days / month 3141 669 1.4 (1
≥ 7 days / month 371 117 2.1 (1
p-trend <0.00
Non migraineous headache 2437 512 1.4 (1
< 7 days / month 2221 443 1.3 (1
≥ 7 days / month 216 69 2.2 (1
p-trend <0.00
Migraine 1075 274 1.7 (1
< 7 days / month 920 226 1.7 (1
≥ 7 days / month 155 48 2.1 (1
p –trend <0.00
*Significant differences (non-overlapping CIs).
All data are adjusted for age, gender, anxiety, depression (total HADS-score) and GI
1: Insomnia = During the last three months difficulty falling asleep at night and / or
able to fall asleep again several days a week.
2: CMSCs = Answered “yes” to the screening question: “Have you during the last ye
and joints?”
Missing data: 155 subjects with pure headache (= 4.2%) and 182 subjects with coex
headache frequency.Discussion
In this large-scale prospective study we found that head-
ache and CMSCs increased the risk of insomnia at
follow-up, most evident among those with headache ≥ 7
days/month, widespread CMSCs and the co-occurrence
of headache and CMSCs at baseline.
Strengths of the present study include a well-defined
population at risk without insomnia and the longitudinalhe combined effect of headache (related to type and
SCs) Coexisting headache and CMSCs
Insomnia1
5% CI) total, n = 11,127 n = 2283 OR (95% CI)
ef) 7263 1080 1.0 (ref)
.3 – 1.6) 3864 1203 2.0 (1.8 – 2.2)*
.2 – 1.6) 3061 920 1.9 (1.7 – 2.2)*
.7 – 2.7) 803 283 2.2 (1.9 – 2.7)
1 <0.001
.2 – 1.5) 2526 766 2.0 (1.7 – 2.2)*
.1 – 1.5) 2058 606 1.9 (1.6 – 2.2)*
.6 – 3.0) 468 160 2.2 (1.8 – 2.8)
1 <0.001
.5 – 2.0) 1338 437 2.0 (1.7 – 2.3)
.4 – 2.0) 1003 314 1.9 (1.7 – 2.3)
.5 – 3.0) 335 123 2.2 (1.7 – 2.8)
1 <0.001
-complaints.
several awakenings during the night and / or wake up to early and were not
ar continuously for at least 3 months had pain and / or stiffness in muscles
isting headache and CMSCs (= 4.5%) did not answer the question on
Table 5 Risk of insomnia1 at 11-year follow-up according to the combined effect of CMSCs2 (non-widespread vs. widespread) and headache (yes/no)
Pure CMSCs (no headache) CMSCs & headache < 7d / month CMSCs & headache ≥7d / month
Insomnia1 Insomnia1 Insomnia1
N, total = 11,558 N, total = 2109 OR (95% CI) N, total = 10,324 N, total = 2000 OR (95% CI) N, total = 8066 OR (95% CI)
No headache or CMSCs 7263 1080 1.0 (ref) 7263 1080 1.0 (ref) 7263 1080 1.0 (ref)
CMSCs2 4295 1029 1.6 (1.4 – 1.7) 3061 920 1.9 (1.7 – 2.2) 803 283 2.2 (1.9 – 2.6)*
Non-widespread CMSCs 2513 540 1.4 (1.3 – 1.6) 1357 339 1.6 (1.4 – 1.9) 262 86 2.2 (1.7 – 3.0)*
Widespread3 CMSCs 1782 489 1.8 (1.5 – 2.0) 1704 581 2.2 (1.9 – 2.5) 541 197 2.2 (1.8 – 2.7)
*Significant differences compared to pure CMSCs (no headache) (non-overlapping CIs).
All data are adjusted for age, gender, anxiety, depression (total HADS-score) and GI-complaints.
1: Insomnia = During the last three months difficulty falling asleep at night and / or several awakenings during the night and / or wake up to early and were not able to fall asleep again several days a week.
2: CMSCs = Have answered “yes” to the screening question: “Have you during the last year continuously for at least 3 months had pain and / or stiffness in muscles and joints?”
3: Widespread CMSCs = CMSCs from all of the following three regions: axial skeleton (neck, upper back, or lower back), above the waist (neck, shoulders, elbows, wrist/hands, or upper back) and below the waist (lower
back, hips, knees, or ankles/feet).
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data allowing separate analyses to evaluate the impact of
pure headache as well as the coexistence of headache
and CMSCs at baseline on the risk of insomnia. Further-
more, we had previously validated the questionnaire-
based headache diagnoses [11], which have sensitivity
estimates varying between 56% and 69% and a high spe-
cificity varying between 89% and 91%. We also found
that the screening question for CMSCs had good reli-
ability [20]. In addition, the present study was relatively
well powered to detect gender differences. To the best of
our knowledge, no previous study has included such a
large number of other relevant health-related variables.
This made it possible to adjust for several potential
confounding variables including anxiety and depression
[30]. Importantly, although we adjusted for anxiety and
depression in the present paper, this does not rule out
the possibility that these disorders are likely to play a
major role in the development of insomnia in subjects
with chronic painful conditions [3,4]. Also, the possibil-
ity of residual confounding by unrecognized factors can-
not be ruled out.
Some limitations should be considered. First, similar
to other relevant prospective studies, the assessment of
insomnia was questionnaire-based. Insomnia may, how-
ever, be present even in the absence of any objective
measures for example by polysomnography [31]. Second,
although the present proxy-insomnia diagnosis has been
used successfully in several other studies [24,25], it has
not yet been validated and it does not fulfill the DSM-IV
criteria for insomnia completely. Both surveys lacked
sufficient information about daytime impairment that is
required in the International Classification of Disease,
ninth (ICD-9) and tenth (ICD-10) edition and the DSM-
IV criteria. As described in the method-section, the
HUNT 3 study did include one question regarding day-
time sleepiness. However, there are conflicting results re-
garding the association between insomnia and subjective
daytime sleepiness [32]. Further, as the daytime conse-
quences vary between different insomnia subtypes [33],
and even from person to person [34], it is unlikely that
one question could capture all individuals with insomnia
causing daytime impairment [34]. The insomnia diagno-
sis in HUNT 2 is also different from the DSM-IV criteria
in another aspect, as the questionnaire did not include
information about the insomnia symptoms beyond one
month. While the ICD-9 and ICD-10 criteria have no re-
quirement on the duration of the insomnia symptoms, it
has to be present for more than one month according to
the second version of the International Classification of
Sleep Disorders (ICSD-2) [35] and the DSM-IV [36].
This makes our insomnia criteria less specific than the
DSM-IV criteria, which might have influenced the re-
sults of the present study. In effort to make thediagnoses more specific we excluded subjects using hyp-
notics or sleep medication from the population at risk in
HUNT 2, and based the diagnosis in HUNT 3 on three
insomnia symptoms instead of two. Ideally the diagnoses
would have been identical in HUNT 2 and HUNT 3, but
unfortunately the insomnia questions in the two surveys
differed a bit.
Third, although 62% of the subjects who answered the
insomnia section of HUNT 2 also answered the insom-
nia section in HUNT 3, a selection bias cannot be ruled
out. The participation rate was moderate at baseline
(58%) and only 29% of the total population completed
the insomnia section in both surveys. Despite this limita-
tion, the HUNT studies include more than 200 health
related variables, which will probably ensure that any
remaining bias relevant to insomnia, headache and
CMSCs is negligible.
Few previous longitudinal studies have evaluated the
influence of headache and CMSCs on the risk of insom-
nia, and no large population-based follow-up study of
adults has similar objectives and study design. In line
with the present results, there is one study of 437 partic-
ipants [8] that reported that unspecified bodily pain was
a risk factor for new-onset insomnia at follow-up 1 year
later. Furthermore, longitudinal studies have found
rheumatoid arthritis [9], painful musculoskeletal condi-
tions [7] and migraine [10] to have a negative influence
on pre-existing sleep difficulties.
In the latter study by Singareddy et al. [10] migraine
was identified as a significant risk factor for insomnia in
the univariate analyses, but not in the multivariate ana-
lyses. However, in their multivariate analyses migraine
was included in a ”mixed group of individuals with phys-
ical health complaints” consisting of e.g. asthma, allergy,
anemia, and kidney disease. The study by Singareddy
et al. also included other important methodological dif-
ferences which may explain divergent results, like differ-
ent population at risk (they included subjects with poor
sleep), different way to diagnose migraine (self rapport
according to ’physical based diagnosis’), and number of
study participants (1246 versus 19,271 in the present
study).
The present study provides evidence that headache
(migraine and non-migraineous) and CMSCs increases
the risk of insomnia. Individuals with persistent head-
ache in both surveys had the strongest association with
insomnia in HUNT 3. The fact that both headache and
CMSCs increased the risk of insomnia might reflect that
the found association is not attributed to either of the
conditions themselves, but more generally linked to the
experience of pain over time. Indeed, several other pain-
ful conditions are linked to poor sleep [7-9]. Further, the
results of the present study were most evident for head-
ache ≥ 7 days / month, in accordance with other studies
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[37]. Interestingly, we have previously identified insom-
nia as a risk factor for primary headaches 11 years later
[26]. Thus, as previous suggested by other studies [38]
there might be a reciprocal relationship between head-
ache and insomnia, with each disorder increasing the
risk of onset of the other. In contrast, in a study on a
mixed group of pain disorders (headache included), pain
was not a reliable predictor for subsequent sleep, while
cognitive arousals could predict the ensuing sleep quality
[39]. In the same study, sleep quality was a predictor of
pain the next day, and good sleep quality relieved pain
the first half of the day [39]. However, this study looked
at the short-time relationship between pain and sleep
[39], which might differ from a long term perspective.
If a reciprocal relationship between headache and in-
somnia do exist, they can be causally related, with in-
somnia causing headache, and vice versa, but one
cannot exclude the possibility of a common neurobio-
logical substrate predisposing to both conditions [38].
Although the exact nature of this bidirectional relation-
ship remains unclear, it might lead to an evil circle
where one disorder exacerbates the other [3]. The trig-
ger might be either of the conditions [40], and regarding
the results of the present study there are several theories
on how pain might lead to sleep difficulties.
One possible mechanism is that chronic pain leads to
structural changes in areas of the brain regulating sleep
[40]. Pain may also cause cognitive pre-sleep arousal,
which disturbs the initiation of sleep [37]. Others believe
that painful conditions like headache might lead to
sleep-seeking behavior to relieve the pain, which in turn
leads to bad sleep habits and insomnia [41].
One interesting aspect of these theories is that better
pain management might relieve sleep difficulties as well
[3]. If there is a bidirectional relationship between pain-
ful conditions and sleep disturbances, patients might
benefit from a more systematic approach to treatment of
insomnia, as well as headache and CMSCs [3]. Further
prospective studies should evaluate whether effective
treatment of headache and CMSCs could prevent future
insomnia.
Conclusion
Headache and CMSCs (particularly frequent headache,
widespread CMSCs or the combination of the two) in-
crease the risk for insomnia after 11 years.
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